| Literature DB >> 36016780 |
Belen Fernandez-Caso1, Ana Miqueleiz2, Verónica B Valdez3, Teresa Alarcón3.
Abstract
Infections produced by Helicobacter pylori (H. pylori), a spiral Gram-negative bacterium, can cause chronic gastritis, peptic ulcer, and gastric cancer. Antibiotic therapy is the most effective treatment for H. pylori infection at present. However, owing to the increasing antibiotic resistance of H. pylori strains, it has become a serious threat to human health. Therefore, the accurate diagnosis of H. pylori infections and its antibiotic resistance markers is of great significance. Conventional microbiological diagnosis of H. pylori is based on culture; however, successful isolation of H. pylori from gastric biopsy specimens is a challenging task affected by several factors and has limitations in terms of the time of response. To improve conventional methods, some molecular techniques, such as PCR, have been recently used in both invasive and non-invasive H. pylori diagnosis, enabling simultaneous detection of H. pylori and point mutations responsible for frequent antibiotic resistance. The advantages and disadvantages of molecular methods, mainly PCR, versus conventional culture for the H. pylori identification and the detection of antibiotic resistance are discussed. As expected, the combination of both diagnostic methods will lead to the most efficient identification of the H. pylori strains and the resistance patterns.Entities:
Keywords: GenoType® HelicoDR test; Helicobacter pylori; PCR; antibiotics; culture; resistance
Year: 2022 PMID: 36016780 PMCID: PMC9396220 DOI: 10.3389/fmicb.2022.962063
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 6.064
Genotypic determination of clarithromycin and levofloxacin resistance mutations by PCR.
| Antibiotic | n (%) | ||
|
| No mutation | 123 (40.2) | |
| Detected mutation | A2146G | 12 (3.9) | |
| A2146C | 2 (0.7) | ||
| A2147G | 165 (53.9) | ||
| Double mutation | 4 (1.3) | ||
|
| 306 (100) | ||
|
| No mutation | 261 (91.6) | |
| Detected mutation | N87K | 9 (3.1) | |
| D91N | 5 (1.7) | ||
| D91G | 6 (2.1) | ||
| D91Y | 4 (1.4) | ||
|
| 285 | ||
*In 21 samples the PCR result for levofloxacin resistance was indeterminate.
Presence or absence of PCR mutations for clarithromycin and levofloxacin versus sensitivity or resistance results by E-test (gold standard).
| Susceptible by | Resistant by | Total | Sensitivity | Specificity | ||
| Clarithromycin PCR | Mutation | 21 (15.4%) | 115 (84.5%) | 136 | 99.1% | 80.0% |
| No mutation | 84 (98.8%) | 1 (1.1%) | 85 | |||
| Levofloxacin PCR | Mutation | 0 (0%) | 16 (100%) | 16 | 100% | 100% |
| No mutation | 198 (100%) | 0 (0%) | 198 | |||